{"text": ["Merck", "&", "Co.\u2019s", "Revenues", "in", "4Q17"], "created_at": "2018-02-14 21:42:21"}
{"text": ["Lilly", "to", "Showcase", "New", "Data", "for", "Taltz\u00ae", "(ixekizumab)", "and", "Other", "Products", "Across", "Immunology", "Pipeline", "at", "AAD", "Annual", "Meeting"], "created_at": "2018-02-14 18:17:00"}
{"text": ["Lilly's", "Taltz", "Positive", "in", "Phase", "III", "Label", "Expansion", "Study"], "created_at": "2018-02-14 17:11:38"}
{"text": ["Lilly's", "Taltz", "Positive", "in", "Phase", "III", "Label", "Expansion", "Study"], "created_at": "2018-02-14 17:11:38"}
{"text": ["Merck", "(MRK)", "Halts", "Another", "Late", "Stage", "Study", "on", "Alzheimer's"], "created_at": "2018-02-14 17:11:32"}
{"text": ["Merck", "(MRK)", "Halts", "Another", "Late", "Stage", "Study", "on", "Alzheimer's"], "created_at": "2018-02-14 17:11:32"}
{"text": ["Bristol-Myers", "Squibb\u2019s", "Valuation", "after", "Its", "4Q17", "Earnings"], "created_at": "2018-02-14 15:31:22"}
{"text": ["Merck", "(MRK)", "Halts", "Another", "Late", "Stage", "Study", "on", "Alzheimer&apos;s"], "created_at": "2018-02-14 14:47:02"}
{"text": ["Lilly&apos;s", "Taltz", "Positive", "in", "Phase", "III", "Label", "Expansion", "Study"], "created_at": "2018-02-14 14:47:02"}
{"text": ["How", "Did", "Pfizer\u2019s", "Viagra", "and", "Lyrica", "Perform", "in", "2017?"], "created_at": "2018-02-14 14:02:47"}
{"text": ["Changes", "in", "Bristol-Myers", "Squibb\u2019s", "4Q17", "Profitability"], "created_at": "2018-02-14 14:01:23"}
{"text": ["Free", "Research", "Report", "as", "Eli", "Lilly\u2019s", "Quarterly", "Revenue", "Jumped", "6%;", "Adjusted", "EPS", "Jumped", "20%"], "created_at": "2018-02-14 12:50:00"}
